Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,852 JPY | -0.16% | -1.40% | -9.17% |
Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
Apr. 24 | Chugai Pharmaceutical's Profit Slightly Up in Q1 | MT |
Business Summary
Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).
Number of employees: 7,604
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceuticals
87.7
%
| 1,039,247 | 82.5 % | 974,493 | 87.7 % | -6.23% |
Other
12.3
%
| 91,915 | 7.3 % | 136,874 | 12.3 % | +48.91% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
50.3
%
| 657,273 | 52.2 % | 559,233 | 50.3 % | -14.92% |
Switzerland
46.1
%
| 482,736 | 38.3 % | 511,880 | 46.1 % | +6.04% |
Overseas
3.6
%
| 119,936 | 9.5 % | 40,253 | 3.6 % | -66.44% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 61 | 87-03-31 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Hisafumi Okabe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Motoo Ueno
BRD | Director/Board Member | 66 | 84-03-31 |
Yoko Kitagawa
IRC | Investor Relations Contact | - | - |
Keiji Kono
IRO | Public Communications Contact | - | - |
Yoshiaki Ohhashi
PRN | Corporate Officer/Principal | - | - |
Yoshiyuki Yano
HRO | Human Resources Officer | - | - |
Shinji Hidaka
SAM | Sales & Marketing | - | - |
Atsushi Sato
AUD | Comptroller/Controller/Auditor | 65 | 81-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Masayuki Oku
BRD | Director/Board Member | 79 | 15-02-28 |
Motoo Ueno
BRD | Director/Board Member | 66 | 84-03-31 |
James H. Sabry
BRD | Director/Board Member | 65 | 19-02-28 |
Christoph Franz
BRD | Director/Board Member | 63 | 17-02-28 |
Director/Board Member | 75 | 17-02-28 | |
William Anderson
BRD | Director/Board Member | 57 | 19-02-28 |
Osamu Okuda
CEO | Chief Executive Officer | 61 | 87-03-31 |
Mariko Momoi
BRD | Director/Board Member | 76 | 20-02-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,679,057,667 | 639,373,741 ( 38.08 %) | 33,675,818 ( 2.006 %) | 38.08 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
33,788,400 | 2.01% | 1,289,069,358 $ | |
ONCOLYS BIOPHARMA INC. 2.25% | 456,600 | 2.25% | 2,380,370 $ |
Company contact information
Chugai Pharmaceutical Co., Ltd.
Nihonbashi Mitsui Tower, 15/F 2-1-1 Nihonbashi-Muromachi
103-8324, Tokyo
+81 3 3281 6611
http://www.chugai-pharm.co.jpSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.17% | 50.71B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4519 Stock
- Company Chugai Pharmaceutical Co., Ltd